Decibel Therapeutics (DBTX)

Company Profile

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

Company profile

Ticker

DBTX

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001656536

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

464198709

DBTX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

21 Mar 23

S-8

Registration of securities for employees

14 Mar 23

Regulation FD Disclosure

10 Mar 23

8-K

Regulation FD Disclosure

9 Nov 22

Departure of Directors or Certain Officers

Departure of Directors or Certain Officers

13 Sep 22

Latest ownership filings

View all

Financial summary

Financial statements Chart DBTX financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	34.61 mm	34.61 mm	34.61 mm	34.61 mm	34.61 mm	34.61 mm
Cash burn (monthly)	691.67 k	154.00 k	5.50 mm	5.33 mm	2.59 mm	4.74 mm
Cash used (since last report)	1.91 mm	425.09 k	15.17 mm	14.71 mm	7.15 mm	13.09 mm
Cash remaining	32.70 mm	34.18 mm	19.44 mm	19.90 mm	27.46 mm	21.52 mm
Runway (months of cash)	47.3	222.0	3.5	3.7	10.6	4.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

DBTX institutional ownership history Ownership history

30.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	41	45	-8.9%
Opened positions	4	10	-60.0%
Closed positions	8	6	+33.3%
Increased positions	10	9	+11.1%
Reduced positions	10	11	-9.1%

13F shares	Current	Prev Q	Change
Total value	697.74 mm	551.86 mm	+26.4%
Total shares	23.09 mm	23.11 mm	-0.1%
Total puts	74.90 k	80.80 k	-7.3%
Total calls	183.20 k	326.50 k	-43.9%
Total put/call ratio	0.4	0.2	+65.2%

Largest owners	Shares	Value	Change
Orbimed Advisors	4.95 mm	$17.11 mm	0.0%
Third Rock Ventures III	3.14 mm	$0.00	0.0%
TRV GP Iii	3.14 mm	$10.86 mm	0.0%
REGN Regeneron Pharmaceuticals	2.10 mm	$9.75 mm	0.0%
BLK Blackrock	1.89 mm	$6.53 mm	-0.4%
Citadel Advisors	1.81 mm	$6.26 mm	+0.9%
GV 2016	1.64 mm	$0.00	0.0%
Samsara BioCapital	801.63 k	$2.77 mm	0.0%
Vanguard	622.94 k	$2.16 mm	0.0%
Bessemer	494.07 k	$1.71 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Ubs Oconnor	157.75 k	+70.00 k	+79.8%
Neuberger Berman	0.00	-69.00 k	EXIT
Millennium Management	317.29 k	+52.72 k	+19.9%
Bridgeway Capital Management	61.98 k	-50.00 k	-44.7%
Dimensional Fund Advisors	41.34 k	+41.34 k	NEW
Geode Capital Management	111.40 k	+40.59 k	+57.3%
EAM Investors	236.97 k	-18.02 k	-7.1%
Two Sigma Securities	0.00	-17.68 k	EXIT
STT State Street	0.00	-17.16 k	EXIT
Citadel Advisors	1.81 mm	+16.68 k	+0.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DBTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Mar 23	Matthew C Kapusta	Common Stock	Grant	Acquire A	No	No	0	10,000	0.00	10,000
19 Mar 23	Matthew C Kapusta	Stock Options Common Stock	Grant	Acquire A	No	No	3.34	10,000	33.40 k	10,000
16 Mar 23	Laurence Reid	Common Stock	Grant	Acquire A	No	No	0	195,000	0.00	220,849
16 Mar 23	Laurence Reid	Stock Options Common Stock	Grant	Acquire A	No	No	3.73	72,000	268.56 k	72,000
26 Jan 23	John Jui-Jen Lee	Common Stock	Grant	Acquire A	No	No	0	120,000	0.00	147,144
26 Jan 23	John Jui-Jen Lee	Stock Options Common Stock	Grant	Acquire A	No	No	3.12	45,000	140.40 k	45,000
26 Jan 23	Anna Trask	Common Stock	Grant	Acquire A	No	No	0	105,000	0.00	106,864
26 Jan 23	Anna Trask	Stock Options Common Stock	Grant	Acquire A	No	No	3.12	45,000	140.40 k	45,000